Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
Eur Rev Med Pharmacol Sci
; 16(7): 952-7, 2012 Jul.
Article
em En
| MEDLINE
| ID: mdl-22953645
ABSTRACT
Osteonecrosis of the jaw (ONJ) is an unremitting adverse outcome associated with bisphosphonate therapy, primarily intravenously administered, in patients with bone metastases from solid tumors, multiple myeloma and osteometabolic diseases. From 2003 many cases of bisphosphonates related osteonecrosis of the jaw (BRONJ) have been reported in literature. Sunititnib is a novel anticancer agent used in gastrointestinal cancers and renal cancers resistant to imatinib. Recent reports describe the onset of ONJ in patients treated with both sunitinib and bisphosponates. A case of osteonecrosis of the jaw related to sunitinib, without association of bisphosphonate (BP) medications has been recently reported. A recent hypothesis suggests that antiangiogenic drugs such as sunitinib could cause ONJ even without the association with BPs. We describe a case of two patients affected by renal carcinoma under BP and sunitinib medication who developed stage III bisphosphonates-related osteonecrosis of the jaw (BRONJ).
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Pirróis
/
Neoplasias Ósseas
/
Carcinoma de Células Renais
/
Inibidores da Angiogênese
/
Difosfonatos
/
Conservadores da Densidade Óssea
/
Osteonecrose da Arcada Osseodentária Associada a Difosfonatos
/
Indóis
/
Neoplasias Renais
Tipo de estudo:
Etiology_studies
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article